Study S002810

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese Participants With Moderate-to-Severe Obstructive Sleep Apnea (OSA) on Positive Airway Pressure (PAP) Therapy（UNISHAPE-OSA-2）

ClinicalTrials.gov record

Registration

Registration: NCT07806851
Acronym: UNISHAPE-OSA-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 150
Start: 2026-10-10
Primary completion: 2029-03
Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Conditions: Obstructive Sleep Apnea; Obesity
Interventions: DRUG:UBT251; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Change from baseline in the Apnea-Hypopnea Index (AHI) [Baseline, Week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.